Live Breaking News & Updates on Assistant Director General Access

Stay updated with breaking news from Assistant director general access. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Increased access to testing, treatment has reduced hepatitis C in low- and middle-income countries

Increased access to testing, treatment has reduced hepatitis C in low- and middle-income countries
Many low- and middle-income countries have reduced suffering from hepatitis C, thanks to increased access to testing and treatment. Some achieved a 20-fold increase in the number of people treated with safe and effective direct-acting retroviral drugs between 2015 and 2018, according to the
Global progress report on accelerating access to hepatitis C diagnostics and treatment, released by WHO today.
A drop in prices underpins this success
Low- and middle-income countries can now aim to achieve a price as low as US$ 60 per patient for a 12-week course of treatment with WHO-prequalified generic sofosbuvir and daclatasvir. Prices offered by suppliers of WHO-prequalified HCV rapid diagnostic tests ranged between US$ 1 and US$ 8 per test. ....

Minghui Ren , Mariangela Simao , Meg Doherty , Emily Henderson , Department Of Global , Health Coverage Communicable , Global Health Sector Strategy On Viral Hepatitis , Health Products , Global Health Sector Strategy , Viral Hepatitis , Assistant Director General Access , Hepatitis C , மெக் டோவர்டீ , எமிலி ஹென்டர்சன் , துறை ஆஃப் உலகளாவிய , ஆரோக்கியம் பாதுகாப்பு தொடர்பு கொள்ளக்கூடியது , உலகளாவிய ஆரோக்கியம் துறை மூலோபாயம் ஆன் வைரஸ் ஹெபடைடிஸ் , ஆரோக்கியம் ப்ராடக்ட்ஸ் , உலகளாவிய ஆரோக்கியம் துறை மூலோபாயம் , வைரஸ் ஹெபடைடிஸ் , உதவியாளர் இயக்குனர் ஜநரல் நுழைவு , சர்வதேச பரவல் ,

WHO on progress in access to hepatitis C diagnostics and treatment

Date Time
WHO on progress in access to hepatitis C diagnostics and treatment
Many low- and middle-income countries have reduced suffering from hepatitis C, thanks to increased access to testing and treatment. Some achieved a 20-fold increase in the number of people treated with safe and effective direct-acting retroviral drugs between 2015 and 2018, according to the Global progress report on accelerating access to hepatitis C diagnostics and treatment, released by WHO today.
A drop in prices underpins this success
Low- and middle-income countries can now aim to achieve a price as low as US$ 60 per patient for a 12-week course of treatment with WHO-prequalified generic sofosbuvir and daclatasvir. Prices offered by suppliers of WHO-prequalified HCV rapid diagnostic tests ranged between US$ 1 and US$ 8 per test. ....

Minghui Ren , Mariangela Simao , Meg Doherty , Department Of Global , Health Coverage Communicable , Global Health Sector Strategy On Viral Hepatitis , Health Products , Global Health Sector Strategy , Viral Hepatitis , Assistant Director General Access , மெக் டோவர்டீ , துறை ஆஃப் உலகளாவிய , ஆரோக்கியம் பாதுகாப்பு தொடர்பு கொள்ளக்கூடியது , உலகளாவிய ஆரோக்கியம் துறை மூலோபாயம் ஆன் வைரஸ் ஹெபடைடிஸ் , ஆரோக்கியம் ப்ராடக்ட்ஸ் , உலகளாவிய ஆரோக்கியம் துறை மூலோபாயம் , வைரஸ் ஹெபடைடிஸ் , உதவியாளர் இயக்குனர் ஜநரல் நுழைவு ,

WHO highlights progress in accelerating access to hepatitis C diagnostics and treatment in low- and middle-income countries

WHO highlights progress in accelerating access to hepatitis C diagnostics and treatment in low- and middle-income countries
WHO / Blink Media - Martyn Aim
©
Credits
WHO highlights progress in accelerating access to hepatitis C diagnostics and treatment in low- and middle-income countries
27 January 2021
Reading time:
Many low- and middle-income countries have reduced suffering from hepatitis C, thanks to increased access to testing and treatment. Some achieved a 20-fold increase in the number of people treated with safe and effective direct-acting retroviral drugs
between 2015 and 2018, according to the
A drop in prices underpins this success
Low- and middle-income countries can now aim to achieve a price as low as US$ 60 per patient for a 12-week course of treatment with WHO-prequalified generic sofosbuvir and daclatasvir. Prices offered by suppliers of WHO-prequalified HCV rapid diagnostic ....

Minghui Ren , Mariangela Simao , Meg Doherty , Department Of Global , Health Coverage Communicable , Global Health Sector Strategy On Viral Hepatitis , Health Products , Global Health Sector Strategy , Viral Hepatitis , Assistant Director General Access , மெக் டோவர்டீ , துறை ஆஃப் உலகளாவிய , ஆரோக்கியம் பாதுகாப்பு தொடர்பு கொள்ளக்கூடியது , உலகளாவிய ஆரோக்கியம் துறை மூலோபாயம் ஆன் வைரஸ் ஹெபடைடிஸ் , ஆரோக்கியம் ப்ராடக்ட்ஸ் , உலகளாவிய ஆரோக்கியம் துறை மூலோபாயம் , வைரஸ் ஹெபடைடிஸ் , உதவியாளர் இயக்குனர் ஜநரல் நுழைவு ,